年轻I期宫颈癌女性保留卵巢后异时性卵巢癌风险
基于SEER数据库1983至2013年4365例50岁以下接受子宫切除术并保留卵巢的I期宫颈癌患者,中位随访10.8年,13例发生异时性卵巢癌,10年和20年累积发生率分别为0.2%和0.5%。年龄≥45岁、非白人种族、腺癌或腺鳞癌组织学及辅助放疗与风险升高相关。
要点
- I期宫颈癌年轻女性保留卵巢后异时性卵巢癌风险低于1%。
- 10年和20年累积发生率分别为0.2%和0.5%。
- 年龄≥45岁、非白人、腺癌/腺鳞癌及辅助放疗与风险升高相关。
核心结论
- I期宫颈癌女性保留卵巢后异时性卵巢癌风险低于1%。
- 年龄较大、非白人种族、腺癌或腺鳞癌组织学及辅助放疗可能与异时性卵巢癌风险升高相关。
研究设计与样本
- 使用监测、流行病学和最终结果计划(SEER)识别1983年至2013年接受子宫切除术并保留卵巢的50岁以下I期宫颈癌女性,共4365例。
- 对宫颈癌诊断后卵巢癌风险进行时间依赖分析。
主要发现
- 宫颈癌诊断时平均年龄37岁,多数为IA期(68.2%)和鳞状细胞组织学(72.9%)。
- 中位随访时间10.8年,13例女性发生异时性卵巢癌。
- 异时性卵巢癌10年累积发生率为0.2%(95%置信区间0.1-0.4),20年为0.5%(95%置信区间0.2-0.8)。
- 异时性卵巢癌诊断时平均年龄47.5岁,55.6%为III-IV期。
- 年龄≥45岁 vs <45岁风险比4.22(95%置信区间1.16-15.4,P=0.018);非白人 vs 白人风险比4.29(95%置信区间1.31-14.0,P=0.009);腺癌或腺鳞癌 vs 鳞癌风险比3.50(95%置信区间1.17-10.5,P=0.028);辅助放疗 vs 无放疗风险比3.69(95%置信区间1.01-13.4,P=0.034)。
关键数值与推荐
- 与无危险因素组相比,1个危险因素风险比范围2.96-8.43,2个危险因素风险比范围16.6-31.0,3-4个危险因素风险比范围62.3-109。
- 异时性卵巢癌10年累积发生率0.2%(95%置信区间0.1-0.4),20年累积发生率0.5%(95%置信区间0.2-0.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While there is an increasing trend of ovarian conservation at the time of surgical treatment for young women with stage I cervical cancer, the risk for subsequent ovarian cancer after ovarian conservation has not been well studied. OBJECTIVE: We sought to examine the incidence of and risk factors for metachronous ovarian cancer among young women with stage I cervical cancer who had ovarian conservation at the time of hysterectomy. STUDY DESIGN: The Surveillance, Epidemiology, and End Results Program was used to identify women aged <50 years who underwent hysterectomy with ovarian conservation for stage I cervical cancer from 1983 through 2013 (n = 4365). Time-dependent analysis was performed for ovarian cancer risk after cervical cancer diagnosis. RESULTS: Mean age at cervical cancer diagnosis was 37 years, and the majority of patients had stage IA disease (68.2%) and squamous histology (72.9%). Median follow-up time was 10.8 years, and there were 13 women who developed metachronous ovarian cancer. The 10- and 20-year cumulative incidences of metachronous ovarian cancer were 0.2% (95% confidence interval, 0.1-0.4) and 0.5% (95% confidence interval, 0.2-0.8), respectively. Mean age at the time of diagnosis of metachronous ovarian cancer was 47.5 years, and stage III-IV disease was seen in 55.6%. Age (≥45 vs <45 years, hazard ratio, 4.22; 95% confidence interval, 1.16-15.4; P = .018), ethnicity (non-white vs white, hazard ratio, 4.29; 95% confidence interval, 1.31-14.0; P = .009), cervical cancer histology (adenocarcinoma or adenosquamous vs squamous, hazard ratio, 3.50; 95% confidence interval, 1.17-10.5; P = .028), and adjuvant radiotherapy use (yes vs no, hazard ratio, 3.69; 95% confidence interval, 1.01-13.4; P = .034) were significantly associated with metachronous ovarian cancer risk. The presence of multiple risk factors was associated with a significantly increased risk of metachronous ovarian cancer compared to the no risk factor group: 1 risk factor (hazard ratio range, 2.96-8.43), 2 risk factors (hazard ratio range, 16.6-31.0), and 3-4 risk factors (hazard ratio range, 62.3-109), respectively. CONCLUSION: Metachronous ovarian cancer risk after ovarian conservation for women with stage I cervical cancer is <1%. Older age, non-white ethnicity, adenocarcinoma or adenosquamous histology, and adjuvant radiotherapy may be associated with an increased metachronous ovarian cancer risk.
引用
- Matsuo K, Machida H, Horowitz MP, et al. Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. Am J Obstet Gynecol. 2017. PMID: 28666700. doi:10.1016/j.ajog.2017.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。